The FXR Agonist, Obeticholic Acid, Suppresses HCC Proliferation & Metastasis: Role of IL-6/STAT3 Signalling Pathway
出版年份 2017 全文链接
标题
The FXR Agonist, Obeticholic Acid, Suppresses HCC Proliferation & Metastasis: Role of IL-6/STAT3 Signalling Pathway
作者
关键词
-
出版物
Scientific Reports
Volume 7, Issue 1, Pages -
出版商
Springer Nature
发表日期
2017-09-26
DOI
10.1038/s41598-017-12629-4
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- FXR blocks the growth of liver cancer cells through inhibiting mTOR-s6K pathway
- (2016) Xiongfei Huang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives
- (2016) Juan P. Arab et al. HEPATOLOGY
- Bile acids and FGF receptors: orchestrators of optimal liver regeneration
- (2015) Hélène Gilgenkrantz et al. GUT
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Farnesoid X receptor associates with β-catenin and inhibits its activity in hepatocellular carcinoma
- (2015) Xijun Liu et al. Oncotarget
- Obeticholic acid for the treatment of primary biliary cirrhosis
- (2015) Palak J Trivedi et al. Expert Review of Clinical Pharmacology
- Knocking on FXR's Door:The "Hammerhead"-Structure Series of FXRs Agonists - Amphiphilic Isoxazoles with Potent In Vitro and In Vivo Activities
- (2014) Christian Gege et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Mechanisms of STAT3 activation in the liver of FXR knockout mice
- (2013) Guodong Li et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
- (2013) Sunder Mudaliar et al. GASTROENTEROLOGY
- Small heterodimer partner overexpression partially protects against liver tumor development in farnesoid X receptor knockout mice
- (2013) Guodong Li et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Downregulation of nuclear receptor FXR is associated with multiple malignant clinicopathological characteristics in human hepatocellular carcinoma
- (2012) Hongying Su et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Cellular and molecular mechanisms of hepatocellular carcinoma: an update
- (2012) Rajagopal N. Aravalli et al. ARCHIVES OF TOXICOLOGY
- FXR ligands protect against hepatocellular inflammation via SOCS3 induction
- (2012) Zhizhen Xu et al. CELLULAR SIGNALLING
- Hepatocarcinogenesis in FXR−/−Mice Mimics Human HCC Progression That Operates through HNF1α Regulation of FXR Expression
- (2012) Nian Liu et al. MOLECULAR ENDOCRINOLOGY
- Hepatocellular Carcinoma
- (2011) Hashem B. El-Serag NEW ENGLAND JOURNAL OF MEDICINE
- Functional Characterization of the Semisynthetic Bile Acid Derivative INT-767, a Dual Farnesoid X Receptor and TGR5 Agonist
- (2010) G. Rizzo et al. MOLECULAR PHARMACOLOGY
- Hepatocellular Carcinoma: Epidemiology, Surveillance, and Diagnosis
- (2010) Morris Sherman SEMINARS IN LIVER DISEASE
- Upregulation of early growth response factor-1 by bile acids requires mitogen-activated protein kinase signaling
- (2009) Katryn Allen et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started